Articles On Respiri (ASX:RSH)

Respiri (RSH) signs a second, five-year, non-exclusive distribution and marketing agreement with Access Telehealth in the United States Access is a premier provider of Remote Patient Monitoring (RPM) and telehealth services utilising their...

Respiri (RSH) secures a second order for Wheezo from mTelehealth Respiri has teamed up with mTelehealth to provide customers with the Wheezo device for evaluation, testing and pilot programs, which are considered the first steps towards se...

The ASX 200 Health Index (XHJ) and the benchmark ASX 200 are trading flat today. Proteomics advances on blood test results Investors gave Proteomics International Laboratories (ASX:PIQ) the thumbs up after the company said it has identified...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

The Respiri Ltd (ASX: RSH) share price leapt 14% to 6.5 cents in early trading this morning. This came following the announcement of a distribution and marketing deal with a United States healthcare company. At the closing bell, Respiri s...

Respiri (RSH) signs a five-year non-exclusive distribution and marketing deal with US-based remote patient monitoring (RPM) and chronic care provider, mTelehealth mTelehealth will initially order US$150,000 (A$208,087) worth of wheezo devi...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Summary Now Respiri’s Wheezo to be sold across pharmacies in Australia Value rises across DEXUS property portfolio BetMakers purchases assets of Form Cruncher and Swopstakes Adacel wins contract for air traffic management, shares ga...

Summary The ASX 200 ended lower by 43.70 points or 0.60% at 7,298.50, led by losses in health care, energy, and banking stock. All sectoral indices, barring tech and materials, ended in red. The market sentiment was dented by concerns...

23 Jun 2021 - A snapshot of notable stock news for the hour, featuring ikeGPS Group, Wide Open Agriculture, Respiri & NeuroScientific Biopharmaceuticals.

23 Jun 2021 - Respiri (ASX:RSH) has announced the commencement of sales of its wheezo asthma-management product across over 570 pharmacies within the Sigma Healthcare (ASX:SIG) net…

The Respiri Ltd (ASX: RSH) share price is racing higher today after the company announced the addition of another pharmacy network for the sale of its wheezo product. Upon the commencement of trade this morning, shares in Respiri increased...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Wall Street rebounds as Nasdaq resets record high All three major US benchmarks rose overnight, as investors adjusted to the Fed’s rate outlook. The Dow Jones rose by 0.20%, S&P 500 by 0.51%, and tech heavy Nasdaq by 0.79%. Nasdaq close...

Fertoz Ltd (ASX:FTZ) topped the pops with a red hot 14-day RSI of 93 after two massive days to finish the week. A total of 18 ASX companies posted a 14-day RSI above 70 last week, down from 25 in the week prior. Each week, Stockhead recaps...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Summary Drug development and clinical services company Emyria has obtained Class IIa TGA registration for its medical-grade monitoring tool, Openly. With this TGA registration, Emyria is in a leading position to develop Real World Evid...

The ASX had a solid start to the week, gaining over 1 per cent and hitting a record high. The ASX 200 closed 1.3 per cent up at 7,172.8 which is a record closing high although not quite an all-time intra day high. The #ASX 200 rose by 92pt...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Themes of the week Healthcare f...

Last year's pandemic put the focus firmly on telehealth services providers, but share prices have deflated since as investors started asking questions, and on the general realisation telehealth has its limits too. -Covid-19 triggered a rush...

Summary Respiri Limited has partnered with Australia’s largest pharmacy network, TerryWhite Chemmart, for the sale and marketing of wheezo™. This agreement brings the total number of pharmacies contracted to stock and sell wheezo to 1,...

The Respiri Ltd Fully Paid Ord. Shrs (ASX: RSH) share price has rocketed 18.2% higher at the market open after an update from the Aussie medical device company. Why is the Respiri share price on the charge? Respiri this morning announced a...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Wall Street mixed as iron ore climbs to record high Wall Street moved modestly overnight. The Dow Jones gained 0.01%, S&P500 lost 0.02%, while tech heavy NASDAQ also fell by 0.34%. Tesla was the biggest name to fall, dropping 4.5%, as y...

Summary With the current emergency, it is anticipated that telehealth or telemedicine could be the future of medicine. COVID-19 pandemic resulted in considerable adoption of telehealth solutions, mainly to avoid physical contact. The...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

Source: DG PhotoStock, Shutterstock Summary ASX-cannabis player Bod Australia has obtained a binding purchase order (PO) for CBD products in the US. Another cannabis player, MGC Pharmaceuticals, has completed the delivery of the first...

This tiny MedTech company, Respiri Ltd [ASX:RSH] managed to quadruple its share price from a low 6 cents in March to around 24 cents in mid-October... The post Are Respiri Shares Set for Another Breakout? (ASX:RSH) appeared first on Money M...

Respiratory health technology company Respiri (ASX: RSH) is trialling a telehealth and remote patient management program in Australia that will also form the basis of the model for the US reimbursement market. Led by leading respiratory phy...

The company’s flagship product Wheezo has received US FDA clearance, with a UK launch scheduled for the end of the year. eHealth MedTech company, Respiri (ASX:RSH), has appointed strategic advisors in Australia and the UK, as part of its pl...

Days after obtaining Food and Drug Administration approval for sales of its wheezo device in the US, Respiri (ASX: RSH) has progressed its international expansion plans with strategic adviser appointments to assist with preparing a UK marke...

Respiri Ltd (ASX: RSH) shares were on the move this morning after the company announced it will be launching its Wheezo brand in the United Kingdom. The Respiri share price opened around 3% higher following the news. However, at the time o...

According to CEO Marjan Mikel, “The regulatory clearance of wheezo and our App in the United States represents a highly significant and major milestone for the company as we continue to expand our regulatory footprint for wheezo and...

Global stock markets dipped Stock markets dipped globally on fears over a potential third lockdown in Europe. Wall Street has seesawed throughout the week, as European shares hit a two-week low. Dow Jones was down 0.01%, S&P 500 fell by...

Respiri (ASX:RSH) has just achieved a huge corporate milestone: its wheeze-detecting device has been approved for sale in the United States, an asthma market that dwarfs any other in the world. Respiri’s wheezo was granted 510(k) clearance...

Source: create jobs 51, Shutterstock Summary MGC Pharmaceuticals has received approval from the Ethics Committee for Phase 3 clinical trial of CimetrATM in COVID-19 patients. eHealth SaaS player Respiri Limited has obtained US FDA’s a...

Wheezo device and app technology developer, Respiri (ASX: RSH) has received the greenlight from the United States Food and Drug Administration (FDA) to market and sell the technology as a class II medical device in the country. The regulato...

The Respiri Ltd (ASX: RSH) share price is on watch today after the company advised it has received United States Food and Drug Administration (FDA) clearance for its Wheezo app.  About Respiri   Respiri is a software-as-a-service (SaaS) co...

Small caps have dipped slightly, while their larger peers have gained. The Small Ordinaries index fell 2.6 points on Monday, or 0.08 per cent, to 3,195.6, while the ASX100 gained 0.73 per cent and the All Ordinaries gained 0.51 per cent. Th...

Small caps have closed lower today, but they finished the week in the green for a second week in a row. The Small Ordinaries index dropped 16.9 points, or 0.5 per cent, on Friday, doing slightly better than their larger peers. The ASX100 fi...

Source: mstanley, Shutterstock On Friday, the market opened lower however, the bulls managed to push the market from the lows to an extent up to the lunch session. However, the selling pressure seeped in and the market declined  towards th...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Special Report: Asthma is the fourth most-prevalent non-communicable disease in the world, killing an estimated 400 Australians each year and ... Read More The post Asthma costs Australia $28 billion a year. Respiri wants to change that. ap...